Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1213
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
ADVAIR DISKUS (Powder)
|
| dailymed-instance:activeIng... | |
| dailymed-instance:boxedWarn... |
WARNING: RISK OF ASTHMA-RELATED DEATH: Long-acting beta-adrenergic agonists, such as salmeterol, one of the active ingredients in ADVAIR DISKUS, may increase the risk of asthma-related death. Therefore, when treating patients with asthma, physicians should only prescribe ADVAIR DISKUS for patients not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies. Data from a large placebo-controlled US study that compared the safety of salmeterol (SEREVENT' Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,176 patients treated for28 weeks on salmeterol versus 3 deaths out of 13,179 patients on placebo) [see Warnings and Precautions (5.1)].
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
fluticasone propionate and salmeterol
|
| dailymed-instance:fullName |
ADVAIR DISKUS (Powder)
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
ADVAIR DISKUS
|